Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy.

被引：0
|
作者：
Nastoupil, Loretta J.
Kamdar, Manali K.
Chavez, Julio C.
Ghesquieres, Herve
Ghosh, Monalisa
Holmes, Houston
Guillermo, Armando Lopez
Martinez-Lopez, Joaquin
Novak, Urban
Ribrag, Vincent
Roddie, Claire
机构：
[1] Univ Texas MD Anderson Canc Ctr Houston, Houston, TX USA
[2] Univ Colorado, Canc Ctr, Aurora, CO USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Hop Lyon Sud, Lyon, France
[5] Univ Michigan Hlth Syst, Ann Arbor, MI USA
[6] Texas Oncol Baylor Charles Sammons Canc Ctr, Dallas, TX USA
[7] Hosp Clin Barcelona, Barcelona, Spain
[8] Hosp 12 Octubre, Madrid, Spain
[9] Univ Hosp Bern, Med Oncol, Inselspital, Bern, Switzerland
[10] Gustave Roussy Canc Ctr DITEP, Villejuif, France
[11] UCL, London, England
[12] Emory Bone Marrow & Stem Cell Transplant Ctr, Winship Canc Inst, Atlanta, GA USA
[13] Hackensack Univ, Hackensack Meridian Hlth Sch Med, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA
[14] Mayo Clin, Phoenix, AZ USA
[15] Mem Sloan Kettering Canc Ctr, New York, NY USA
[16] Univ klinikum Carl Gustav Carus Dresden, Dresden, Germany
[17] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[18] Bristol Myers Squibb Co, Celgene, Boudry, Switzerland
[19] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7526
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Subgroup analyses of primary refractory vs early relapsed Large B-cell Lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs Standard of Care (SOC) as second-line (2L) therapy
    Glass, B.
    Nastoupil, L.
    Kamdar, M.
    Chavez, J. C.
    Ghesquieres, H.
    Ghosh, M.
    Holmes, H.
    Lopez-Guillermo, A.
    Martinez-Lopez, J.
    Novak, U.
    Ribrag, V
    Roddie, C.
    Waller, E. K.
    Feldman, T.
    Rosenthal, A. C.
    Sauter, C.
    von Bonin, M.
    Karmali, R.
    Montheard, S.
    Previtali, A.
    Abramson, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 210 - 211
  • [2] Lisocabtagene Maraleucel (Liso-cel) vs Standard of Care (SOC) with Salvage Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) as Second-Line Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 TRANSFORM Study
    Glass, B.
    Abramson, J. S.
    Solomon, S. R.
    Arnason, J. E.
    Johnston, P. B.
    Bachanova, V
    Ibrahimi, S.
    Mielke, S.
    Mutsaers, P.
    Hernandez-Ilizaliturri, F.
    Izutsu, K.
    Morschhauser, F.
    Lunning, M. A.
    Crotta, A.
    Montheard, S.
    Previtali, A.
    Kamdar, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 272 - 273
  • [3] Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study
    Abramson, Jeremy S.
    Solomon, Scott R.
    Arnason, Jon E.
    Johnston, Patrick B.
    Glass, Bertram
    Bachanova, Veronika
    Ibrahimi, Sami
    Mielke, Stephan
    Mutsaers, Pim
    Hernandez-Ilizaliturri, Francisco
    Izutsu, Koji
    Morschhauser, Franck
    Lunning, Matthew A.
    Crotta, Alessandro
    Montheard, Sandrine
    Previtali, Alessandro
    Kamdar, Manali
    BLOOD, 2022, 140 : 1581 - 1583
  • [4] COST EFFECTIVENESS OF THE CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL TREATMENT LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE (2L) TREATMENT OF RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN SWITZERLAND
    Deger, K.
    Oniangue-Ndza, C.
    Elsada, A.
    Litkiewicz, M.
    Villalobos, Franco C.
    Sorensen, S.
    VALUE IN HEALTH, 2023, 26 (12) : S152 - S153
  • [5] USE OF EXTERNAL CONTROL DATA TO ADJUST FOR TREATMENT SWITCHING IN COST-EFFECTIVENESS ANALYSES: LISOCABTAGENE MARALEUCEL (LISO-CEL) VERSUS STANDARD OF CARE (SOC) IN SECOND-LINE RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
    Chandler, C.
    Liu, F. F.
    Klijn, S.
    Elsada, A.
    Proskorovsky, I
    VALUE IN HEALTH, 2023, 26 (12) : S407 - S408
  • [6] POST-INFUSION MONITORING COSTS BY SITE OF CARE AMONG PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (LBCL) WHO RECEIVED SECOND-LINE TREATMENT WITH LISOCABTAGENE MARALEUCEL (LISO-CEL) IN THE TRANSFORM STUDY: A UNITED STATES SUBGROUP ANALYSIS
    McGarvey, N.
    Vaidya, N.
    Gitlin, M.
    Lee, A.
    Ung, B.
    Carattini, T.
    Keating, S. J.
    VALUE IN HEALTH, 2022, 25 (07) : S389 - S389
  • [7] Phase 3 TRANSFORM study of lisocabtagen maraleucel (Liso-Cel), a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy, versus standard of care (SOC) as second-line therapy (2L) in patients (pt) with relapsed or refractory large B-cell lymphoma (LBCL)
    Glass, B.
    Kamdar, M.
    Solomon, S. R.
    Arnason, J.
    Johnston, P. B.
    Ibrahimi, S.
    Mielke, S.
    Mutsaers, P.
    Hernandez-Ilizaliturri, F.
    Izutsu, K.
    Morschhauser, F.
    Lunning, M.
    Maloney, D. G.
    Crotta, A.
    Montheard, S.
    Previtali, A.
    Stepan, L.
    Ogasawara, K.
    Abramson, J. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 194 - 194
  • [8] Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)
    Abramson, Jeremy S.
    Kamdar, Manali
    Liu, Fei Fei
    Crotta, Alessandro
    Previtali, Alessandro
    Klijn, Sven L.
    Wang, Pearl
    Situ, Aaron
    Zhang, Yixie
    Bonner, Ashley
    Lunning, Matthew A.
    BLOOD, 2022, 140 : 4655 - 4656
  • [9] Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study.
    Sehgal, Alison
    Hoda, Daanish
    Riedell, Peter A.
    Ghosh, Nilanjan
    Hamadani, Mehdi
    Hildebrandt, Gerhard
    Godwin, John E.
    Reagan, Patrick Michael
    Wagner-Johnston, Nina D.
    Essell, James
    Nath, Rajneesh
    Solomon, Scott R.
    Champion, Rebecca
    Licitra, Edward
    Fanning, Suzanne
    Gupta, Neel K.
    Dubowy, Ronald L.
    D'Andrea, Aleco
    Wang, Lei
    Gordon, Leo I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study
    Abramson, Jeremy S.
    Solomon, Scott R.
    Arnason, Jon E.
    Johnston, Patrick B.
    Glass, Bertram
    Crotta, Alessandro
    Montheard, Sandrine
    Previtali, Alessandro
    Liu, Fei Fei
    Braverman, Julia
    Guo, Shien
    Shi, Ling
    Kamdar, Manali
    BLOOD, 2021, 138 : 3845 - +
12345